Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.
BACKGROUND
New therapeutic modalities are needed for non-small cell lung cancer (NSCLC) patients whose tumors have become resistant to gefitinib.


METHODS
Between 2005 and 2008, 16 NSCLC patients, who had been previously treated with gefitinib and evaluated as partial response or complete response according to the response evaluation criteria in solid tumors (RECIST), received gefitinib plus paclitaxel. Paclitaxel was administered at 60 mg/m(2) on days 1, 8 and 15 every 4 weeks, and gefitinib was administered at 250 mg/day from the first day of administration of paclitaxel.


RESULTS
The response rate and disease control rate were 13% and 75%, respectively. The median progression-free survival (PFS) and median overall survival were 4.3 months and 8.1 months, respectively. The toxicities were mild, and there were no treatment-related deaths.


CONCLUSIONS
Gefitinib plus paclitaxel after failure of gefitinib exhibits activity and acceptable toxicity.
Shukuya
Takehito
T
Division of Thoracic Oncology, Shizuoka Cancer Center, Suntou-gun, Shizuoka 411-8777, Japan. tshukuya@juntendo.ac.jp
Takahashi
Toshiaki
T
Tamiya
Akihiro
A
Ono
Akira
A
Igawa
Satoshi
S
Nakamura
Yukiko
Y
Tsuya
Asuka
A
Murakami
Haruyasu
H
Naito
Tateaki
T
Kaira
Kyoichi
K
Endo
Masahiro
M
Yamamoto
Nobuyuki
N
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D016019:Survival Analysis
D011799:Quinazolines; D017239:Paclitaxel; D000077156:Gefitinib